Welcome to CrownBio’s Blog where we share our thoughts
on the latest trends and hot stories in Oncology and CVMD

May 4, 2021 For the Children: Advancing the Cause of Pediatric Cancer Research Why are cancer treatments for children lagging behind the latest advancements in clinical oncology? CrownBio Director Mike Batey takes a closer look at pediatric cancer and how recent regulatory changes and additional research focus may deliver new therapies for kids. Each year approximately 400,000 children from infants to teenagers are diagnosed with ... LEARN MORE
April 1, 2021 Expanding the Horizon of Antibody-Drug Conjugates for Cancer Treatment This post explores the fast-expanding topic of antibody-drug conjugates (ADCs), including those that have been approved ... LEARN MORE
March 1, 2021 Profiling of Tumor-Infiltrating Immune Cells in Syngeneic Tumor Models to Support Drug Development Tumor-Infiltrating Immune Cells: Explore how the identification and quantification of tumor-infiltrating lymphocytes ... LEARN MORE
December 18, 2020 Factors to Consider When Selecting a Next Generation Sequencing (NGS) Technology Explore the main factors you need to consider before choosing and using next generation sequencing (NGS). LEARN MORE
December 16, 2020 Germ-Free or Antibiotic-Treated Mice? Which Model for Studying the Role of the Gut Microbiota in Preclinical Studies Explore the differences and similarities of germ-free (GF) and antibiotic-treated mice as models for studying the role ... LEARN MORE
December 3, 2020 The Latest Developments on PARP Inhibitors for Prostate Cancer Treatment Review the status of PARP inhibitors (PARPi) for prostate cancer treatment, with a focus on recent developments in drug ... LEARN MORE
November 30, 2020 The Rising Importance of GITR Agonists as Alternative I/O Candidates for Combination Drug Strategies Explore why glucocorticoid-induced TNFR-related protein (GITR or CD357) agonists are becoming increasingly important as alternative immunotherapy candidates for combination therapies. LEARN MORE
November 10, 2020 SHP2 and SOS1 Targets: Additional Players in the KRAS Inhibitors Race? Explore why upstream KRAS-mutant targets, such as SHP2 and SOS1, may lead to optimized therapeutic combinations for ... LEARN MORE
November 6, 2020 In Vivo Imaging of Syngeneic Models for Immuno-Oncology Studies Explore how different imaging modalities are used to monitor in vivo immuno-oncology (I/O) studies in syngeneic tumor ... LEARN MORE
October 26, 2020 Applications and Benefits of Engineered Syngeneic Cell Lines Explore the use and main benefits of engineered syngeneic cell lines for investigating drug targets and biological ... LEARN MORE
October 21, 2020 Meet the CrownBio Team: Dr Marrit Putker, Organoid Research Scientist Meet the newest member of CrownBio’s organoid team, Marrit Putker, heading up research at our new Utrecht site. LEARN MORE
October 14, 2020 Evaluating Immunotherapy Mechanism of Action with Immune Cell Lineage-Specific DTR Models Explore how transgenic diphtheria toxin receptor (DTR) preclinical models are used to better understand immunotherapy ... LEARN MORE
October 2, 2020 Next Generation Syngeneic Models: Top 14 Questions Dr Davy Ouyang, CrownBio Vice President of Scientific Research & Innovation answers the most popular questions from his ... LEARN MORE
September 22, 2020 T Cell Dysfunction Assays for In Vitro Screening of Immunomodulatory Drug Candidates Review the latest advances in the recall antigen assay, to provide an optimized system for screening and characterizing ... LEARN MORE
September 17, 2020 HUB Technology: The Only Tumor Organoid Platform Available for Oncology Drug Discovery Explore why adult stem cell (ASC)-derived HUB technology provides the only tumor organoid platform available for ... LEARN MORE